ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34.

ABSTRACT:

Aim

To investigate the performance of the Xpert® Breast Cancer STRAT4 (CE-IVD∗) Assay (STRAT4) in the neoadjuvant, randomized Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 34.

Patients and methods

The primary objective of this study was to assess the concordance between STRAT4 mRNA measurements of ESR1, PGR, ERBB2, and MKi67 obtained from diagnostic core biopsies of the ABCSG Trial 34 with central reference laboratory immunohistochemistry (IHC) (and in-situ hybridization for HER2 IHC 2+ samples). For each marker, overall percent agreement (concordance), positive percent agreement (sensitivity), and negative percent agreement (specificity) between STRAT4 and IHC were determined. The secondary objective was to evaluate the concordance of STRAT 4 and IHC in po

SUBMITTER: Kacerovsky-Strobl S 

PROVIDER: S-EPMC12639300 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature